Where does Crinetics Pharmaceuticals's cash flow data come from?

Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$496.39M-51.2%	-$465.32M-55.9%	-$423.1M-52.2%	-$369.83M-43.0%	-$328.25M-39.4%
Depreciation and amortization	$4.13M+27.5%	$3.89M+39.7%	$3.68M+63.1%	$3.44M+95.3%	$3.24M+151%
Stock-based compensation	$100.23M+31.2%	$91.02M+31.2%	$88.15M+41.8%	$83.59M+51.8%	$76.41M+65.1%
Gain (loss) on sale of assets	-$51K—	-$50K—	——	——	——
Change in accounts receivable	——	——	——	——	$0—
Change in inventories	——	——	——	——	$0—
Change in accounts payable	——	——	——	$17.96M+40.4%	$10.66M-29.0%
Change in other assets	——	——	$26.34M—	$21.19M—	$13.1M—
Change in deferred revenue	——	——	——	——	-$305.5K+73.0%
Non-cash operating lease expense	——	——	——	——	——
Change in operating lease liabilities	——	——	——	——	——
Net cash from operating activities	-$414.17M-55.8%	-$377.92M-64.2%	-$351.89M-72.4%	-$304M-66.4%	-$265.79M-47.1%
Capital expenditures	$5.34M+42.4%	$5.76M+49.9%	$6.33M+68.9%	$6M-10.8%	$3.75M-37.5%
Purchases of investments	$1.17B-18.8%	$1B-12.4%	$1.52B+155%	$1.43B+93.8%	$1.44B+138%
Proceeds from maturities/sales of investments	$1.18B+51.2%	$1.18B+106%	$1.1B+129%	$865.63M+108%	$780.9M+113%
Net cash from investing activities	$7.51M+101%	$173.91M+129%	-$425.29M-202%	-$590.1M-76.7%	-$681.69M-174%
Proceeds from issuance of common stock	$380.51M-4.4%	$0-100%	$32.1K-100.0%	$48.17M-95.6%	$398.17M-47.1%
Net cash from financing activities	$426.05M-31.9%	$40.61M-96.0%	$570.81M+14.5%	$625.05M-19.8%	$625.52M-20.2%
Effect of exchange rate changes on cash	——	——	——	——	$0—
Net increase (decrease) in cash	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$13.27M-14.2%	$15.43M+3.3%	$16.85M+17.4%	$16.77M+38.7%	$15.46M+61.2%
Operating lease liabilities	——	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$26.34M—	$21.19M—	$13.1M—
Operating lease right-of-use asset amortization	——	——	——	——	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$1.18B+51.2%	$1.18B+106%	$1.1B+129%	$865.63M+108%	$780.9M+113%
Payments Of Stock Issuance Costs	——	——	——	——	$11.24M+171%
Proceeds from exercise of stock options and shares issued under Employee Stock Purchase Plan	——	$40.61M-9.0%	$41.61M+6.7%	$42.61M+27.5%	$43.61M+56.8%
Amounts accrued for offering costs	——	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	——	——	$0—
Increase Decrease In Operating Lease Liability	——	——	——	——	——
Stock options exercised receivable	——	——	$4.8M—	——	——
Private company shares received under licensing arrangements	——	$0—	$0-100%	$0-100%	$0-100%
Stock held in trust	——	——	——	$112K—	——
Free cash flow	-$419.52M-55.6%	-$383.68M-63.9%	-$358.23M-72.3%	-$310M-63.7%	-$269.54M-44.3%
Free cash flow	-$419.52M-55.6%	-$383.68M-63.9%	-$358.23M-72.3%	-$310M-63.7%	-$269.54M-44.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Crinetics Pharmaceuticals's cash flow data come from?: Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.